|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||3.3188 - 3.3899|
|52 Week Range||3.3188 - 3.3899|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The cannabis sector remains hot for mergers and acquisitions as companies rush to capture a piece of the recreational cannabis market. Last week, Canopy Growth (WEED) announced that it had acquired Annabis Medical, an importer and distributor of medical cannabis in the Czech Republic. Last week, Cannabis Wheaton announced its acquisition of a licensed producer in Nova Scotia, Robinson’s Cannabis, which is constructing a 27,700-square-foot facility ahead of the legalization of recreational cannabis in Canada.
Hydropothecary (HYYDF) continued its upward momentum and closed 1.5% higher on April 12, 2018. The company and its peers (MJ) Canopy Growth (WEED), Aphria (APHQF), MedReleaf (MEDFF), and Aurora Cannabis (ACB) completed supply agreements with SAQ (Société des alcools du Québec). You can find out more at Why Hydropothecary Stock Rose 13% Yesterday.
On April 11, Hydropothecary (HYYDF) stock surged 13.2% after it became the SAQ’s (Société des alcools du Québec) preferred non-medical cannabis supplier once non-medical cannabis becomes legal in Canada. The company’s press release stated that the agreement term extends to the first five years following legalization and has an option to extend for another year.
Emerging businesses often serve as excellent chances to earn outsized profits. One rising out of the shadows recently is the marijuana industry. Bans instituted in the early 20th century drove its cultivation and use of cannabis underground. However, with various trends toward legalization, marijuana stocks have gained interest from investors.
Hydropothecary (HYYDF) reported a fall during fiscal 2Q18 due to a big increase in its operating expense YoY (year-over-year). The company’s operating expense rose from 1.7 million Canadian dollars in fiscal 2Q17 to 5.5 million Canadian dollars in fiscal 2Q18. Standardizing this as a percentage of its sales, Hydropothecary’s operating expenses rose from 1.9x its sales in fiscal 2Q17 to 4.6x its sales in fiscal 2Q18.
Earlier in this series, we learned that Hydropothecary (HYYDF) experienced a 29% YoY (year-over-year) increase in sales in its fiscal 2Q18. Driving this sales figure higher was the 45% YoY growth in the medical cannabis space. In all, the company sold 132,000 grams (or ~132 kilograms) of medical cannabis during the quarter.
Companies that have significant growth prospects for profitability and returns can add tangible upside to your portfolio. Real Matters and Distinct Infrastructure Group are examples of many potential outperformers thatRead More...
Ahead of the legalization of recreational cannabis, companies are ramping up their production capacities. Currently, Canada has a total of 91 licensed producers, of which 48 are in the province of Ontario. How a province goes about selecting its supplier will be critical for big and small players alike.
Interest in who is investing in the marijuana industry is mounting rapidly, and not without a reason. Over the first five weeks of 2018, the Viridian Cannabis Deal Tracker registered $1.23 billion in ...
Seattle, Washington--(Newsfile Corp. - December 7, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an exclusive CEO interview and article discussing The Hydropothecary Corporation (TSXV: THCX) and its focus on developing award-winning products while also scaling up cannabis production capacity in a province that could give it near-exclusive supply rights.Strategic Presence in QuebecCanada's projected growth in the cannabis industry is driven by ...
Seattle, Washington--(Newsfile Corp. - November 8, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering the innovative product lines offered by The Hydropothecary Corporation (TSXV: THCX), focusing on the Decarb product line comprised of fine milled, activated medical marijuana powders.Canada's cannabis industry is expected to reach $22.6 billion in size over the coming years, according to Deloitte, driven by the ...
Seattle, Washington--(Newsfile Corp. - October 19, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article discussing the Hydropothecary Corporation (TSXV: THCX) and its unique position in the burgeoning cannabis industry. Canada's cannabis industry is expected to balloon to C$22.6 billion over the coming years, according to Deloitte, following the legalization of adult-use cannabis. With about 60 licensed producers approved by Health ...
Hydropothecary Announces Upsize of Previously Announced Bought Deal Private Placement Financing to $25.0 million
As previously announced, each convertible debenture unit will consist of $1,000 principal amount of 8.0% senior unsecured convertible debentures of the Company (the "Convertible Debentures") and 313 common share purchase warrants (the "Warrants") of the Company (the "Offering"). The Convertible Debentures will bear interest from the date of closing at 8.0% per annum, payable semi-annually on June 30 and December 31 of each year and will mature on June 30, 2019 (the "Maturity Date"). The Convertible Debentures will be convertible at the option of the holder into common shares of the Company at any time prior to the close of business on the Maturity Date at a conversion price of $1.60 per share (the "Conversion Price").